Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.Con.Res. 85 Budget Resolution (Spratt) health-related provisions; H.R. 1, American Recovery and Reinvestment Act (Obey) health information technology, privacy, comparative effectiveness research, prevention and wellness; H.R. 15, National Health Insurance Act (Dingell) single-payer health reform (continued)

H.R. 109, America's Affordable Health Care Act (Fortenberg) essential benefits plan, high risk pools; H.R. 193, AmeriCare Health Care Act (Stark) new government health program; H.R. 544, Flexible Health Savings Act (Royce) FSA rollovers; H.R. 598, Economic Recovery Provisions (Rangel) health information technology, privacy; H.R. 629, Economic Recovery Provisions (Waxman) health information technology, privacy; H.R. 676, United States National Health Care Act (Conyers) single payer health reform; H.R. 679, Economic Recovery Provisions (Obey) health information technology, privacy, comparative effectiveness research, prevention and wellness; H.R. 1086, Help Efficient, Accessible, Low-cost, Timely Healthcare Act (Gingrey) medical liability reform; H.R. 1105, Omnibus Appropriations Act (Obey) high risk pools, comparative effectiveness research; H.R. 1200, American Health Security Act (McDermott) single-payer health reform; H.R. 1468, Medical Justice Act (Burgess) medical liability reform; H.R. 1493, Quality Health Care Coalition Act (Paul) antitrust exemption for physicians; H.R. 1658, Veterans Healthcare Commitment Act (Tiahrt) third party billing by VA for service-connected disabilities; H.R. 1721, CLASS Act (Pallone) national LTC program; S.Con.Res. 13 Budget Resolution (Conrad) health-related provisions; S. 45, Medical Care Access Protection Act (Ensign) medical liability reform; S. 179, Health Information Technology Act (Stabenow) health information technology; S. 336, Economic Recovery Provisions (Inouye) health information technology, privacy, comparative effectiveness research; S. 350, Economic Recovery Provisions (Baucus) health information technology; S. 697, CLASS Act (Kennedy) national LTC program; S. 698, State-Based Health Care Reform Act (Feingold) pilot projects for state-based health reforms; S. 703, American Health Security Act (Sanders) single-payer health reform

HCR (Regulatory Issues):

HIPAA administrative simplification issues, including standards for privacy, security, and electronic transactions and code sets; FEHBP enrollment data clearinghouse initiative; issues relating to health insurance plan participation in FEHBP, including contract requirements related to interoperability of health information technology, community rating policies, and similarly sized subscriber group (SSSG) requirement; implementation of the health savings account provisions of the Medicare Act; issues related to Medicare Secondary Payer requirements; issues related to implementation of the National Health Information Infrastructure; issues relating to market consolidation; issues relating to quality improvement; issues related to potential priority research topics for the effective health care program; issues related to provider conscience requirements; issues relating to the national health data stewardship; issues relating to hospital outpatient measurement and reporting; issues related to genetics and genetic nondiscrimination; and issues relating to Form 5500 reporting requirements.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Treasury - Dept of, Federal Trade Commission (FTC), Office of Personnel Management (OPM), Agency for Health Care Policy & Research, Internal Revenue Service (IRS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 1, American Recovery and Reinvestment Act (Obey) Medicaid FMAP; H.R. 2, Children's Health Insurance Program Reauthorization Act (Pallone) CHIP expansion; H.R. 629, Economic Recovery Provisions (Waxman) Medicaid FMAP, Medicaid option for unemployed; H.R. 684, Medicare Prescription Drug Savings and Choice Act (Berry) Part D reforms (continued)

H.R. 904, Medicaid Prescription Drug Rebate Equalization Act (Stupak) Medicaid drug costs; H.R. 1407, Medicare Part D Home and Community Services Copayment Equity Act (Doggett) Part D cost sharing; H.R. 1670, Community Choice Act (Davis) Medicaid coverage; H.R. 1832, Medicare Prescription Drug Affordability Act (Wexler) Part D reforms; S.Con.Res. 13 Budget Resolution (Conrad) Medicare Advantage funding; S. 75, Generics First Act (Kohl) Part D reforms; S. 266, Medicare Prescription Drug Gap Reduction Act (Nelson) Part D reforms; S. 275, Children's Health Insurance Program Reauthorization Act (Baucus) CHIP expansion; S. 330, Medicare Prescription Drug Savings and Choice Act (Durbin) Part D reforms; S. 350, Economic Recovery Provisions (Baucus) Medicaid FMAP; S. 534, Home and Community Services Copayment Equity Act (Nelson) Part D reforms; S. 547, Drug Rebate Equalization Act (Bingaman) Medicaid drug costs; S. 677, REPAIR Act (Ensign) means-testing Part D premiums; S. 683, Community Choice Act (Harkin) Medicaid coverage

MMM (Regulatory Issues)
Ongoing implementation issues for the Medicare Advantage (MA) and Medicare Part D prescription drug programs, including risk adjustment methodology and data issues, (including audit and encounter data issues), bidding and payment issues (including MA rate assumptions, MA coding intensity, Part D reinsurance, Part D low income subsidies, and audits), application process, audits to evaluate compliance with MA and Part D program rules, benefit design rules, SSA and CMS premium withhold processing issues, enrollment rules, marketing materials review and approval, marketing activities, including conduct and compensation of brokers and agents and plan sponsor marketing staff, measurement and oversight of plan performance including Special Needs Plans (SNPs); quality measures, grievance and appeals processes, compliance/fraud and abuse training, and Medicare/Medicaid integration issues for Special Needs Plans (SNPs); Federal preemption of State authority under MA and Part D programs, Part D prescription drug event data reporting, Part D formulary rules, Part D pharmacy access standards, and other operational issues; Medicare creditable drug coverage reporting requirements; implementation issues for the Medicare Retiree Drug Subsidy program; functionality of the Medicare Personal Plan Finder and Drug Plan Finder; National Medicare Education program; ongoing implementation issues for the Medicare cost plan program including enrollment, marketing materials review and approval and other operational issues, MA and Part D systems issues affecting enrollment and disenrollment processing and payment and other operational issues; Medicare demonstration program on performance-based payments for physician groups; physician quality reporting initiative; issues relating to Medicare coverage policy and national coverage decisions; Medicare clinical trials; Medicaid managed care regulations and policies, including the Medicaid managed care actuarial soundness standard, quality oversight, grievance and appeals processes, beneficiary information requirements, treatment of Medicaid health plan member hospital days in the upper payment limit calculation; policies affecting State Medicaid funding, including intergovernmental transfers (IGTs); coordination of benefits with state Medicaid programs; Medicaid prescription drug cost/rebate issues affecting Medicaid health plans; health plan-related State Childrens Health Insurance Program (SCHIP) issues, including eligibility and outreach issues; implementation of Medicaid changes made in Deficit Reduction Act of 2005, including documentation of citizenship requirements, state benefit flexibility options, and Medicaid managed care organization provider tax issues; standards for electronic prescribing; and health information technology standards and policies.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act (Waxman) generic biologics; H.R. 1548, Pathway for Biosimilars Act (Eshoo) generic biologics (continued)

H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act (Schumer) generic biologics


PHA (Regulatory):
Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Personnel Management (OPM), Drug Enforcement Administration (DEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code INS

16. Specific lobbying issues

H.R. 1, American Recovery and Reinvestment Act (Obey) COBRA; H.R. 323, Comprehensive Insurance Coverage of Childhood Immunization Act (Green) immunization coverage mandate; H.R. 584, Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act (Lee) coverage mandate for hormone replacement therapy; H.R. 598, Economic Recovery Provisions (Rangel) COBRA (continued)

H.R. 629, Economic Recovery Provisions (Waxman) COBRA; H.R. 697, Family Building Act (Weiner) coverage mandate for infertility treatments; H.R. 716, Access to Cancer Clinical Trials Act (Israel) clinical trials coverage mandate; H.R. 850, Small Business CHOICE Act (Velazquez) small employer health options; H.R. 859, Small Business CHOICE Act (Velazquez) small employer health options; H.R. 995, Mammogram and MRI Availability Act (Nadler) coverage mandate for mammograms; H.R. 1085, Health Insurance Coverage Protection Act (Eshoo) lifetime benefit limits; H.R. 1092, No Discrimination in Health Insurance Act (Kagen) preexisting condition exclusions, affiliation periods, uniform premiums; H.R. 1253, Health Insurance Restrictions and Limitations Clarification Act (Burgess) disclosure of coverage exclusions; H.R. 1321, Healthy Americans Act (Eshoo) comprehensive health reform; H.R. 1330, Colorectal Cancer Screening and Detection Coverage Act (Boren) coverage mandate for cancer screening; H.R. 1339, Children's Access to Reconstructive Evaluation & Surgery Act (McCarthy) coverage mandate for treatment of a child's congenital or developmental deformity; H.R. 1558, Preexisting Condition Patient Protection Act (Courtney) preexisting condition exclusions; H.R. 1583, Insurance Industry Competition Act (DeFazio) McCarran Ferguson reforms; H.R. 1619, Children's Health Protection Act (Schwartz) preexisting condition exclusions for children; H.R. 1691, Breast Cancer Patient Protection Act (DeLauro) rescissions, hospital stays for breast cancer patients; S. 79, Healthy Businesses, Healthy Workers Reinsurance Act (Kerry) reinsurance; S. 93, Small Business Empowerment Act (Brown) small employer health options; S. 350, Economic Recovery Provisions (Baucus) COBRA; S. 391, Healthy Americans Act (Wyden) comprehensive health reform; S. 442, Health Insurance Coverage Protection Act (Dorgan) lifetime benefit limits; S. 488, Access to Cancer Clinical Trials Act (Brown) clinical trials coverage mandate; S. 623, Pre-existing Condition Patient Protection Act (Rockefeller) preexisting condition exclusions; S. 643, Children's Health Protection Act (Lautenberg) preexisting condition exclusions for children; S. 688, Breast Cancer Patient Protection Act (Snowe) rescissions, hospital stays for breast cancer patients

INS (Regulatory)
Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; issues relating to the coordination of benefits between private health insurance plans and Medicaid; crossover fees for Medigap claims; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials; implementation of the Mental Health Parity Act requirements; issues related to COBRA subsidy requirements, and issues related to genetic nondiscrimination.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Treasury - Dept of, Social Security Administration (SSA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R. 1, American Recovery and Reinvestment Act (Obey) TAA health care tax credits; H.R. 897, Long-Term Care and Retirement Security Act (Putnam) tax incentives for LTC insurance; S. 94, Long-Term Care Family Accessibility Act (Vitter) tax incentives for LTC insurance; S. 702, Long-Term Care Affordability and Security Act (Grassley) tax incentives for LTC insurance (continued)



TAX (Tax) Regulatory: Issues relating to Health Savings Accounts; issues related to COBRA subsidy requirements; and issues relating to withholding of government contract payments.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address: http://www.ahip.org/content/default.aspx?bc=31|42|54

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization